Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tristen S Park

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Oncology (Williston Park, N.Y.)|September 17, 2016
Current Trends in the Management of Ductal Carcinoma In SituTristen S Park, E Shelley Hwang
Trends in Biotechnology|June 14, 2011
Treating cancer with genetically engineered T cellsTristen S Park, Steven A Rosenberg, Richard A Morgan
Annals of Surgical Oncology|June 22, 2023
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the RestLeah Kim, Magdalena Coman, Lajos Pusztai, et al.
Cancers|May 14, 2025
Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast CancerIsmail Ajjawi, Alejandro Rios, Wei Wei, et al.
Breast Cancer Research and Treatment|May 14, 2025
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancerIsmail Ajjawi, Alejandro Rios, Wei Wei, et al.
Nucleic Acid Therapeutics|July 15, 2014
Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteinsTristen S Park, Daniel Abate-Daga, Ling Zhang, et al.
JAMA Surgery|July 2, 2020
Association of Medicaid Expansion Under the Affordable Care Act With Breast Cancer Stage at DiagnosisJustin M Le Blanc, Danielle R Heller, Ann Friedrich, et al.
Current Treatment Options in Oncology|July 2, 2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic TherapyJulia Foldi, Mariya Rozenblit, Tristen S Park, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 8, 2015
Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic CancersTristen S Park, Eric M Groh, Krishna Patel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2023
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast CancerMagdalena M Coman, Lajos Pusztai, Regina Hooley, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Oncology (Williston Park, N.Y.)|September 17, 2016
Current Trends in the Management of Ductal Carcinoma In SituTristen S Park, E Shelley Hwang
Trends in Biotechnology|June 14, 2011
Treating cancer with genetically engineered T cellsTristen S Park, Steven A Rosenberg, Richard A Morgan
Annals of Surgical Oncology|June 22, 2023
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the RestLeah Kim, Magdalena Coman, Lajos Pusztai, et al.
Cancers|May 14, 2025
Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast CancerIsmail Ajjawi, Alejandro Rios, Wei Wei, et al.
Breast Cancer Research and Treatment|May 14, 2025
Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancerIsmail Ajjawi, Alejandro Rios, Wei Wei, et al.
Nucleic Acid Therapeutics|July 15, 2014
Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteinsTristen S Park, Daniel Abate-Daga, Ling Zhang, et al.
JAMA Surgery|July 2, 2020
Association of Medicaid Expansion Under the Affordable Care Act With Breast Cancer Stage at DiagnosisJustin M Le Blanc, Danielle R Heller, Ann Friedrich, et al.
Current Treatment Options in Oncology|July 2, 2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic TherapyJulia Foldi, Mariya Rozenblit, Tristen S Park, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 8, 2015
Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic CancersTristen S Park, Eric M Groh, Krishna Patel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2023
Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast CancerMagdalena M Coman, Lajos Pusztai, Regina Hooley, et al.
Pageof 2